Physician profile
Gary T Evans
NPI 1346200904
$1,418.64
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $166 · 2021: $357 · 2022: $403 · 2023: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $180 · Entertainment: $18.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $179.55 |
| Entertainment | $18.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $209.77 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $128.94 | 2022-2023 | |
| Novo Nordisk INC | $112.96 | 2019-2022 | |
| Abbvie INC. | $105.47 | 2021-2023 | |
| Dexcom, INC. | $79.71 | 2021-2023 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $64.48 | 2019-2022 | |
| Stryker Corporation | $64.07 | 2021 | |
| Mylan Specialty L.P. | $61.12 | 2021 | |
| Glaxosmithkline, LLC. | $55.82 | 2021-2023 | Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $55.27 | 2019-2022 | |
| Astellas Pharma US INC | $48.05 | 2019-2020 | |
| Eisai INC. | $41.52 | 2020 | |
| Sumitomo Pharma America, INC. | $35.87 | 2023 | Gemtesa |
| Lilly USA, LLC | $32.67 | 2022 | |
| Allergan, INC. | $30.24 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $28.64 | 2020-2022 | |
| Amgen INC. | $27.02 | 2019-2020 | |
| Philips North America LLC | $26.76 | 2022 | |
| Merck Sharp & Dohme LLC | $25.54 | 2020-2022 | |
| Insulet Corporation | $21.65 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.22 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $19.87 | 2023 | Austedo |
| Otsuka America Pharmaceutical, INC. | $19.63 | 2022 | |
| Optos, INC. | $18.50 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.17 | 2019 | |
| Vifor Pharma, INC. | $12.29 | 2021 | |
| Alnylam Pharmaceuticals INC. | $12.04 | 2020 | |
| Mdd US Operations, LLC | $11.99 | 2019 | |
| Medtronic Minimed, INC. | $11.98 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.72 | 2020 | |
| Avanir Pharmaceuticals, INC. | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.